COVID-19 testing solutions

We offer various testing solutions that are used across the world today to support fast and trustworthy diagnosis:

  • A qualitative molecular rapid detection kit based on real-time fluorescent reverse transcription isothermal amplification and testing of nasopharyngeal swab samples, oropharyngeal swab samples and saliva specimens. This fast assay takes 70 min from sample to result and does not require RNA extraction.
  • A qualitative molecular detection kit based on real-time fluorescent reverse transcription amplification and testing of nasopharyngeal swab, nasal swab, nasal aspirates and washes, oropharyngeal swab, BAL, and sputum specimens. This assay gives results within 75 minutes and does require RNA extraction. A rapid version of 3 genes (+/- 40 min) is to be expected in September.
  • A high-sensitive antigen assay running on our fully automated chemiluminescent platform, capable of testing both nasopharyngeal swab fluid and saliva samples and giving fast results, in up to 30 minutes.
  • A highly sensitive and specific quantitative antibody assay to SARS-CoV-2 Spike (S) RBD protein running on our fully automated CLEIA platform capable of testing both serum and plasma samples and giving fast results, in up to 30 minutes. A quantitative antibody assay to SARS-CoV-2 nucleocapsid protein is also expected in October 2021.
  • A lateral flow-based rapid antigen test that does not require any special equipment. This portable single assay device evaluates nasopharyngeal swab fluid, it uses a simple procedure and has a short time to result of only 30 minutes.

Furthermore, thanks to our long-lasting and extensive experience in lung disease testing we also offer associated testing solutions that allow to predict disease severity in patients infected with SARS-CoV-2.

 

 

 

Read more below or contact us today